Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy

Cancer Letters

Volumn 279, Issue 2, 2009, Pages 163-170

  Wu, Fei Xiang ^a   Wang, Qi ^a   Zhang, Zhi Ming ^a   Huang, Shang ^a   Yuan, Wei Ping ^a   Liu, Jian Yong ^a   Ban, Ke Chen ^b   Zhao, Yin Nong ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Biomarker; Hepatocellular carcinoma; Proteomics; Serum; Surface enhanced laser desorption ionization time of flight mass spectroscopy

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; PROTEIN; THROMBIN; THROMBIN LIGHT CHAIN; UNCLASSIFIED DRUG;

ARTICLE; CLASSIFICATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; GROWTH RELATED ONCOGENE ALPHA; HEPATITIS B; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; LIGHT CHAIN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DATABASE; PROTEOMICS; RANDOM SAMPLE; SENSITIVITY AND SPECIFICITY; SEROLOGY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; UPREGULATION;

ALPHA-FETOPROTEINS; AMINO ACID SEQUENCE; CARCINOMA, HEPATOCELLULAR; CHEMOKINE CXCL1; HEPATITIS B; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MOLECULAR SEQUENCE DATA; MULTIVARIATE ANALYSIS; PROTEOME; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; THROMBIN; TUMOR MARKERS, BIOLOGICAL;

EID: 67349146749     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.01.034     Document Type: Article

References (25)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94 (2001) 153-156
2. Pisani P., Parkin D.M., Bray F., and Ferlay J. Erratum: estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer 83 (1999) 18-29
3. Schwegler E.E., Cazares L., Steel L.F., Adam B.L., Johnson D.A., Semmes O.J., Block T.M., Marrero J.A., and Drake R.R. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 41 (2005) 634-642
4. Johnson P.J. The role of serum a-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin. Liver Dis. 5 (2001) 145-151
5. Soga K., Watanabe T., Aikawa K., Toshima M., Shibasaki K., and Aoyagi Y. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma. Hepatogastroenterology 45 (1998) 1737-1741
6. Lee I.N., Chen C.H., Sheu J.C., Lee H.S., Huang G.T., Yu C.Y., Lu F.J., and Chow L.P. Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry. J. Proteome Res. 4 (2005) 2062-2069
7. Li C., Tan Y.X., Zhou H., Ding S.J., Li S.J., Ma D.J., Man X.B., Hong Y., Zhang L., Li L., Xia Q.C., Wu J.R., Wang H.Y., and Zeng R. Proteomic analysis of hepatitis B virus-associated hepatocellular carcinoma: identification of potential tumor markers. Proteomics 5 (2005) 1125-1139
8. Li J., Zhang Z., Rosenzweig J., Wang Y.Y., and Chan D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48 (2002) 1296-1304
9. Adam B.L., Qu Y., Davis J.W., Ward M.D., Clements M.A., Cazares L.H., Semmes O.J., Schellhammer P.F., Yasui Y., Feng Z., and Wright Jr. G.L. Serum protein fingerprinting coupled with a patternmatching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62 (2002) 3609-3614
10. Yu Y., Chen S., Wang L.S., Chen W.L., Guo W.J., Yan H., Zhang W.H., Peng C.H., Zhang S.D., Li H.W., and Chen G.Q. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncology 68 (2005) 79-86
11. Zhang Z., Jr Bast R.C., Yu Y., Li J., Sokoll L.J., Rai A.J., Rosenzweig J.M., Cameron B., Wang Y.Y., Meng X.Y., Berchuck A., Van Haaften-Day C., Hacker N.F., de Bruijn H.W., van der Zee A.G., Jacobs I.J., Fung E.T., and Chan D.W. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64 (2004) 5882-5890
12. Paradis V., Degos F., Dargere D., Pham N., Belghiti J., Degott C., Janeau J.L., Bezeaud A., Delforge D., Cubizolles M., Laurendeau I., and Bedossa P. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 41 (2005) 40-47
13. J. Bruix, M. Sherman, J.M. Llovet, M. Beaugrand, R. Lencioni, A.K. Burroughs, E. Christensen, L. Pagliaro, M. Colombo, J. Rodes, EASL Panel of Experts on HCC (2001) Clinical management of hepatocellular carcinoma: Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver, J. Hepatol. 35 (2001) 421-430.
14. Erlinger S., and Benhamou J.P. Cirrhosis: clinical aspects. In: Bircher J., Benhamou J.P., McIntyre N., Rizetto M., and Rodes J. (Eds). Oxford Textbook of Clinical Hepatology. second ed. (1999), Oxford University Press, Oxford 629-641
15. Tirumalai R.S., Chan K.C., Prieto D.A., Issaq H.J., Conrads T.P., and Veenstra T.D. Characterization of the low molecular weight human serum proteome. Mol. Cell Proteomics 2 (2003) 1096-1103
16. Petricoin E.F., and Liotta L.A. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr. Opin. Biotechnol. 15 (2004) 24-30
17. Poon T.C., Yip T.T., Chan A.T., Yip C., Yip V., Mok T.S., Lee C.C., Leung T.W., Ho S.K., and Johnson P.J. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin. Chem. 49 (2003) 752-760
18. Marrero J.A., Su G.L., Wei W., Emick D., Conjeevaram H.S., Fontana R.J., and Lok A.S. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 37 (2003) 1114-1121
19. Grazi G.L., Mazziotti A., Legnani C., Jovine E., Miniero R., Gallucci A., Palareti G., and Gozzetti G. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transplant. Sur. 1 (1995) 249-255
20. Brunello F., Marcarino C., Pasquero P., Gastaldi P., Gonella S., Martini S., Calcamuggi G., and Emanuelli G. The des-gamma-carboxyprothrombin for the diagnosis of hepatocellular carcinoma. Ital J. Gastroenterol. 25 (1993) 9-12
21. Coussens L.M., and Werb Z. Inflammation and cancer. Nature (Lond) 420 (2002) 860-867
22. Diamandis E.P. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J. Natl. Cancer Inst. (Bethesda) 96 (2004) 353-356
23. Matrisian L.M., Sledge Jr. G.W., and Mohla S. Extracellular proteolysis and cancer: meeting summary and future directions. Cancer Res. 63 (2003) 6105-6109
24. Yousef G.M., and Diamandis E.P. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev. 22 (2001) 184-204
25. Balentien E., Myfson B.E., and Shattuck R.L. Effects of MGSA/GRO-α on melanocyte transformation. Oncogene 6 (1991) 1115-1124